We've gone from what was considered an undruggable mutation to now having almost an embarrassment of riches as far as RAS therapeutics. We can now target multiple different variants, and we have 2 FDA-approved drugs for G12C. With that said,...
Lung cancer remains the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for approximately 85% of cases [1]. Lung adenocarcinoma is the most common histological subtype of NSCLC and frequently harbors actionable driver alterations. KRAS mutations...
Credit: magicmine / Getty Images A comprehensive genomic profiling study involving more than 13,000 patients has shown that targetable G12C mutations in the KRAS oncogene are rare in genitourinary cancers, potentially limiting the role of routine testing and targeted treatment...
BridgeBio Oncology Therapeutics (Nasdaq: BBOT) released new clinical data for its KRASG12C inhibitor BBO-8520, according to a company press release, showing response rates in non-small cell... BridgeBio Oncology Therapeutics (Nasdaq: BBOT) released new clinical data for its KRASG12C inhibitor BBO-8520,...
